CH625213A5 - - Google Patents

Download PDF

Info

Publication number
CH625213A5
CH625213A5 CH704576A CH704576A CH625213A5 CH 625213 A5 CH625213 A5 CH 625213A5 CH 704576 A CH704576 A CH 704576A CH 704576 A CH704576 A CH 704576A CH 625213 A5 CH625213 A5 CH 625213A5
Authority
CH
Switzerland
Prior art keywords
formula
ppm
multiplet
thienyl
trans
Prior art date
Application number
CH704576A
Other languages
German (de)
English (en)
Inventor
Wilhelm Dr Bartmann
Gerhard Dr Beck
Dieter-Bernd Dr Reuschling
Karl Dr Seeger
Hermann Dr Teufel
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of CH625213A5 publication Critical patent/CH625213A5/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/54Quaternary phosphonium compounds
    • C07F9/5407Acyclic saturated phosphonium compounds
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09JADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
    • C09J7/00Adhesives in the form of films or foils
    • C09J7/10Adhesives in the form of films or foils without carriers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CH704576A 1975-06-05 1976-06-03 CH625213A5 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2524955A DE2524955C3 (de) 1975-06-05 1975-06-05 Neue Thienyl-Prostaglandine und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
CH625213A5 true CH625213A5 (ja) 1981-09-15

Family

ID=5948288

Family Applications (1)

Application Number Title Priority Date Filing Date
CH704576A CH625213A5 (ja) 1975-06-05 1976-06-03

Country Status (20)

Country Link
US (1) US4258053A (ja)
JP (3) JPS527954A (ja)
AT (1) AT360671B (ja)
AU (1) AU517489B2 (ja)
BE (1) BE842687A (ja)
CA (1) CA1086722A (ja)
CH (1) CH625213A5 (ja)
DE (1) DE2524955C3 (ja)
DK (1) DK152675C (ja)
ES (1) ES448387A1 (ja)
FR (1) FR2313036A1 (ja)
GB (1) GB1553914A (ja)
HU (1) HU175238B (ja)
IE (1) IE43849B1 (ja)
IL (1) IL49716A (ja)
IT (1) IT1061525B (ja)
LU (1) LU75076A1 (ja)
MX (1) MX3609E (ja)
NL (1) NL188693C (ja)
SE (2) SE430158B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04107991U (ja) * 1991-02-26 1992-09-17 テーダブリユ電気株式会社 ヘツドホン
WO2016153094A1 (ko) * 2015-03-26 2016-09-29 비스메르 주식회사 3-알콕시싸이오펜 유도체의 신규한 제조방법
CN106146455A (zh) * 2015-03-30 2016-11-23 维斯曼株式会社 3-烷氧基噻吩衍生物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3956284A (en) * 1972-07-13 1976-05-11 Pfizer Inc. Heterocyclic 15-substituted-ω-pentanorprostoglandins
GB1428137A (en) * 1972-09-27 1976-03-17 Ici Ltd Prostanoic acid derivatives
GB1431561A (en) * 1973-01-31 1976-04-07 Ici Ltd Cyclopentane derivatives
US3931279A (en) * 1973-05-21 1976-01-06 The Upjohn Company 5-Oxa prostaglandin F2.sub.α analogs
US3932289A (en) * 1973-11-09 1976-01-13 Chevron Research Company Preparation of overbased carbonated sulfurized magnesium alkylphenates
GB1484591A (en) * 1974-04-11 1977-09-01 Ono Pharmaceutical Co Prostaglandin compositions

Also Published As

Publication number Publication date
MX3609E (es) 1981-03-31
IL49716A0 (en) 1976-08-31
IE43849L (en) 1976-12-05
GB1553914A (en) 1979-10-10
DK152675B (da) 1988-04-11
LU75076A1 (ja) 1977-03-07
DK248176A (da) 1976-12-06
JPS61246181A (ja) 1986-11-01
FR2313036B1 (ja) 1979-06-29
AT360671B (de) 1981-01-26
AU517489B2 (en) 1981-08-06
AU1460176A (en) 1977-12-08
DE2524955B2 (de) 1981-02-12
IL49716A (en) 1980-10-26
CA1086722A (en) 1980-09-30
JPS61243075A (ja) 1986-10-29
SE430158B (sv) 1983-10-24
ES448387A1 (es) 1977-08-01
IE43849B1 (en) 1981-06-17
IT1061525B (it) 1983-04-30
JPS527954A (en) 1977-01-21
HU175238B (hu) 1980-06-28
JPS6210233B2 (ja) 1987-03-05
DE2524955C3 (de) 1981-12-03
DK152675C (da) 1988-10-31
JPS6261592B2 (ja) 1987-12-22
JPS6261593B2 (ja) 1987-12-22
SE7910057L (sv) 1979-12-06
FR2313036A1 (fr) 1976-12-31
BE842687A (fr) 1976-12-08
US4258053A (en) 1981-03-24
ATA413676A (de) 1980-06-15
NL7605856A (nl) 1976-12-07
DE2524955A1 (de) 1977-03-17
SE7606318L (sv) 1976-12-06
SE445112B (sv) 1986-06-02
NL188693C (nl) 1992-09-01

Similar Documents

Publication Publication Date Title
DE69716226T2 (de) Difluoroprostaglandin-Derivate und ihre Anwendung
DE2731868A1 (de) 15-deoxy-16-hydroxy-16-substituierte- prostansaeuren, derivate hiervon und verfahren zu ihrer herstellung
DE2355731C3 (de) Derivate von w -nor-Prostaglandinen- E2IUId -F2 a , Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Zusammensetzungen Pfizer Ine, New York, N.Y. (YStA.)
DE2517771A1 (de) Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
DE2416193C2 (de) Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie ihre Verwendung als cytoprotektives Mittel
DE2460990A1 (de) Neue prostaglandin-analoga und verfahren zu ihrer herstellung
DE2626888A1 (de) 11-desoxy-16-aryloxy-omega-tetranorprostaglandine
CH646147A5 (de) 4,5-ungesaettigte prostansaeurederivate.
DE2830079A1 (de) Neue prostaglandinderivate der delta 2,4-11-desoxy-pge-reihe
DE2737808A1 (de) 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine
DE2422924A1 (de) Thiaprostaglandine
CH634831A5 (en) Process for the preparation of optically active or racemic prostaglandins.
CH625213A5 (ja)
DE2610503C2 (de) Optisch aktive 13,14-Dehydro-11- desoxy-prostaglandine, Verfahren zu ihrer Herstellung und sie enthaltendes pharmazeutisches Mittel
DE2910474C2 (ja)
DE2743283A1 (de) Neue prostacyclin-analoga
CH623570A5 (ja)
DD140745A5 (de) Verfahren zur herstellung von neuen prostaglandinen
DE2541883C2 (de) 9-Oxo-15xi-hydroxy-20-alkylidenprost-13(trans)-ensäurederivate und Verfahren zu ihrer Herstellung und diese enthaltendes Arzneimittel
DE2704932A1 (de) Prostaglandin-analoga mit dreifachbindung zwischen c-13 und c-14 und verfahren zu ihrer herstellung
DE2709347A1 (de) Erythro-15,16-dioxyprostensaeuren und -ester sowie verfahren zu ihrer herstellung
DE2463432C2 (ja)
DE2357953A1 (de) Neue, natuerlich nicht vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
DE2640692C3 (de) Optisch aktive 5- (2-Carboxythiophen5-yl)-16phenoxy- a -tetranor- w tetranor-prostaglandine
EP0001255B1 (de) Neue fluorhaltige Prostaglandinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Legal Events

Date Code Title Description
PL Patent ceased